Journal Article

Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine

Zhu, Shanli, Zhao, Kong‐Nan, Xiang, Yunru, Feng, Weixu, Chen, Zhuo, Chen, Na, Wu, Lianpeng, Chen, Jun, Guo, Yanru, Zhang, Lifang, Xia, Dandan, Li, Qingfeng

2022

Overview

Background SARS‐CoV‐2 has spread worldwide causing more than 400 million people with virus infections since early 2020. Currently, the existing vaccines targeting the spike glycoprotein (S protein) of SARS‐CoV‐2 are facing great challenge from the infection of SARS‐CoV‐2 virus and its multiple S protein variants. Thus, we need to develop a new generation of vaccines to prevent infection of the SARS‐CoV‐2 variants. Compared with the S protein, the nucleocapsid protein (N protein) of SARS‐CoV‐2 is more conservative and less mutations, which also plays a vital role in viral infection. Therefore, the N protein may have the great potential for developing new vaccines. Methods The N protein of SARS‐CoV‐2 was recombinantly expressed and purified in Escherichia coli. Western Blot and ELISA assays were used to demonstrate the immunoreactivity of the recombinant N protein with the serum of 22 COVID‐19 patients. We investigated further the response of the specific serum antibodies and cytokine production in BALB/c mice immunized with recombinant N protein by Western Blot and ELISA. Results The N protein had good immunoreactivity and the production of IgG antibody against N protein in COVID‐19 patients was tightly correlated with disease severity. Furthermore, the N protein was used to immunize BALB/c mice to have elicited strong immune responses. Not only high levels of IgG antibody, but also cytokine‐IFN‐γ were produced in the N protein‐immunized mice. Importantly, the N protein immunization induced a high level of IgM antibody produced in the mice. Conclusion SARS‐CoV‐2 N protein shows a great big bundle of potentiality for developing a new generation of vaccines in fighting infection of SARS‐CoV‐2 and its variants. The SARS‐CoV‐2 N protein shows a great big bundle of potentiality for developing a new generation of vaccines in fighting SARS‐CoV‐2 infection.

• Publisher: John Wiley & Sons, Inc,John Wiley and Sons Inc
• Subject: Adenoviruses / Amino acids / Animals / Antibodies / Antibodies, Viral / antibody / Coronaviruses / COVID-19 / COVID-19 - prevention & control / COVID-19 vaccines / Cytokines / Disease transmission / E coli / Enzyme-linked immunosorbent assay / Experiments / Gene expression / Humans / Immune response / Immunization / Immunoglobulin G / Immunoglobulin M / Immunoreactivity / Infections / Interferon / Laboratory animals / Measles / Mice / Mice, Inbred BALB C / Mutation / N protein / nucleocapsid protein / Nucleocapsid Proteins / Nucleocapsids / Proteins / SARS-CoV-2 / Severe acute respiratory syndrome coronavirus 2 / Spike glycoprotein / Spike Glycoprotein, Coronavirus - genetics / vaccine / Vaccines / Viruses